Skip to main content
Signal8

Neuphoria Therapeutics Inc. (NEUP)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Neuphoria Therapeutics Inc. logo

Neuphoria Therapeutics Inc.

NASDAQ:NEUPHealthcare
AH+0.00%$2.76
Close$2.76-0.72%
Mkt Cap$14.94M
Float4.5M
O/S5.41M
VOL24K sh
$ Vol$66K
RVOL0.68×
Inst Own37.3%
Dilution
Neuphoria Therapeutics Inc. logoNASDAQ:NEUPAH$2.76+0.00%
Historical Data
DateOpenHighLowCloseVolume
Nov 9, 20262.802.862.752.7623,995
Nov 6, 20262.732.832.732.7819,632
Nov 5, 20262.972.982.702.7740,038
Nov 4, 20263.053.072.982.9877,555
Nov 3, 20263.053.052.992.997,872
Nov 2, 20263.143.142.993.0452,454
Oct 30, 20263.103.113.043.0570,250
Oct 29, 20263.323.323.033.0670,087
Oct 28, 20263.403.423.323.3638,920
Oct 27, 20263.483.483.383.393,639
Oct 26, 20263.393.463.353.3826,699
Oct 23, 20263.463.593.373.4473,020
Oct 22, 20263.463.563.463.484,799
Oct 21, 20263.493.543.463.488,798
Oct 20, 20263.373.403.333.3920,808
Oct 19, 20263.243.413.243.3139,509
Oct 16, 20263.353.413.243.3076,418
Oct 15, 20263.253.423.253.3118,748
Oct 14, 20263.323.373.243.2445,955
Oct 13, 20263.493.493.323.3926,637
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
1
HOLD
1
SELL
0
TOTAL2
Insider Trades
InsiderTypeShares
Wilson David Ian profile photoWilson David IanGrant/Award8.5K
Ryan Jane profile photoRyan JaneGrant/Award8.5K
Fisher Alan profile photoFisher AlanGrant/Award17.1K
Davies Peter Miles Winston profile photoDavies Peter Miles WinstonGrant/Award8.5K
Lynx1 Capital Management LP profile photoLynx1 Capital Management LPPurchase639.1K
Papapetropoulos Spyros profile photoPapapetropoulos SpyrosGrant/Award34.6K
Shareholders
37.3%
Institutional
(20)
0.0%
Insiderⓘ
(0)
9.7%
5%+ Owners
(3)
53.0%
Unattributed (incl. retail)ⓘ
Institutional37.3%
5%+ Beneficial9.7%
Unattributed (incl. retail)53.0%
Top Shareholders
NameShares%
Point72 Asset Management, L.P. logo
Point72 Asset Management, L.P.
· may incl. warrants· filed Feb 2024
59.6M4.0% as filed
Armistice Capital, LLC logo
Armistice Capital, LLC
· may incl. warrants· filed Feb 2025
1.0M5.0% as filed
Lynx1 Capital Management LP logo
Lynx1 Capital Management LP
· also on 13F· may incl. warrants· filed Dec 2025
875.3K16.2%
Lynx1 Capital Management LP logo
Lynx1 Capital Management LP
875.3K16.2%
AdvisorShares Investments LLC logo
AdvisorShares Investments LLC
312.9K5.8%
AdvisorShares Trust logo
AdvisorShares Trust
· also on 13F· may incl. warrants· filed Oct 2026
312.9K5.8%
Coastlands Capital LP logo
Coastlands Capital LP
· joint filing· may incl. warrants· filed Jul 2026
228.6K4.2%
Baselake Partners, LP logo
Baselake Partners, LP
· may incl. warrants· filed Feb 2026
222.2K4.1%
VANGUARD CAPITAL MANAGEMENT LLC logo
VANGUARD CAPITAL MANAGEMENT LLC
173.5K3.2%
Shay Capital LLC logo
Shay Capital LLC
· also on 13F· may incl. warrants· filed Oct 2025
171.6K3.2%
Sources: 13F, Form 4, 13D/13GO/S: 5.4M · as of 17 Sep 2026 · SEC filings
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials.

Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders.

The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.

Key Metrics
Market Cap$14.94M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership37.28%

based on 5.41M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateDec 16, 2021
Shares Outstanding5.41M
Authorized Shares
Float4.50M
52-Week Range
$2.70$5.53
$2.76(2nd percentile)
Volume
Average Daily Volume34.96K
24.00K today vs 34.96K avg(-31%)

30d Avg

34.96K

60d Avg

24.02K

90d Avg

31.99K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...